FTC orders biggest ever divestiture in Teva Allergan deal
The US Federal Trade Commission (FTC) has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.
As previously reported in July, under the order Teva was required to divest the rights and assets related to 79 pharmaceutical products to 11 firms.
Among the divested products are anaesthetics, antibiotics, weight loss drugs and oral contraceptives.
The products will be distributed to Mayne Pharma, Impax Laboratories, Dr Reddy’s Laboratories, Sagent Pharmaceuticals, Cipla, Zydus Worldwide, Mikah Pharma, Perrigo Pharma, Aurobindo Pharma, Prasco and 3M Company.
The drug divestiture is the largest such order in an FTC pharmaceutical merger case.
Erez Vigodman, Teva CEO, said in July: “We are pleased to have received all of the requisite regulatory approvals for our acquisition of Actavis Generics [Allergan].”
Debbie Feinstein, director of the FTC’s bureau of competition, said in a statement at the time: “Millions of Americans rely daily on generic drugs to treat a wide range of illnesses.”
She added: “The FTC’s settlement safeguards the competitive availability of these medications for patients across the country who depend on them.”
The FTC examined not only particular product overlaps, but also whether the combination between Teva and Allergan would result in other adverse consequences to competition.
In July, the FTC said in a statement: “We concluded that the substantial divestitures required by the consent order resolve the competitive concerns resulting from the transaction.”
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk